With over two decades of professional experience and more than ten years specifically dedicated to the high-stakes world of pharmacovigilance, Anuradha Prabhakar stands as a leading voice in the digital transformation of drug safety. As an Associate Director of Product Management at IQVIA, she has witnessed firsthand how the industry has shifted from manual workflows to data-driven ecosystems. Our conversation delves into the delicate balance between rapid AI adoption and the necessity of robust governance, exploring how organizations can navigate regional regulatory friction, overcome the hurdles of scaling technology, and maintain the essential human element in safety reporting. We examine the emerging themes of transparency and trust that are currently reshaping how we protect patient safety in a world of unprecedented data volume.
Global regulatory bodies often prioritize different aspects of AI, such as validation rigor in one region and data privacy in another. How can pharmacovigilance teams effectively navigate these conflicting priorities without compromising their operational efficiency?
The reality is that we are operating in a fragmented landscape where “compliance” is no longer a static goalpost but a moving target. When one country demands extreme validation rigor and system oversight while another focuses heavily on data privacy and sovereignty, it creates significant friction that can stall even the most advanced teams. To navigate this, leaders must stop treating compliance as a reactive exercise and instead build forward-thinking strategies that are adaptable enough to absorb these regional nuances. In my experience, the key is to establish a risk-based governance framework that acts as a baseline, ensuring that no matter the local requirement, the core principles of data stewardship and transparency are already met. It is about creating a “single source of truth” in your process that allows for localized adjustments without reinventing the entire workflow every time a new guideline is published in a different jurisdiction.
A 2025 report highlighted that most organizations still struggle to move past AI pilots into full-scale implementation. From your perspective, what are the missing links required to bridge the gap between a successful experiment and a global rollout?
Moving past the pilot phase requires a level of operational discipline that many organizations find daunting because it forces them to confront the limitations of their existing infrastructure. The report from 2025 by McKinsey was a wake-up call for the industry, showing that while we are great at proving a concept, we often stumble when it comes to scaling those workflows with consistent effectiveness. The missing link is usually a lack of robust governance; you cannot scale a pilot if you haven’t defined the clear boundaries of how that AI will interact with human experts at a global volume. We need to focus on “explainability”—the ability to clearly demonstrate how an AI model reached a conclusion—because without that, trust breaks down the moment you move from a controlled pilot to a real-world application. Scaling is less about the technology itself and more about the maturity of the governance frameworks that support it, ensuring that every automated step is backed by clear accountability.
With the “human-in-the-loop” approach being so central to current discussions, how do you define the boundary between what AI should automate and where an expert’s judgment must remain final?
The boundary is drawn at the point where a decision impacts a patient’s life directly; while AI is incredible at processing repetitive and time-consuming tasks, it lacks the nuanced expert judgment required for final safety outcomes. Pharmacovigilance teams are under constant pressure to detect adverse events quickly, and AI can certainly surface potential risks from massive datasets that would take a human weeks to comb through. However, we must ensure that automation enhances rather than replaces professional expertise, particularly when it comes to the interpretation of complex, unstructured data. We use AI to clear the “background noise” and handle the heavy lifting of data organization, but the final safety decisions must remain grounded in the experience of a human who understands the clinical context. This balance reinforces accountability and ensures that we are using technology to modernizing operations without sacrificing the regulatory rigor that the heart of safety reporting demands.
The explosion of data from digital channels like social platforms and connected devices has made identifying meaningful signals increasingly difficult. What strategies are most effective for separating these signals from the background noise?
The sheer volume of safety-relevant information coming from social platforms, call centers, and digital devices has created a defining challenge for modern pharmacovigilance, making traditional manual approaches feel increasingly strained. To separate meaningful signals from the noise, we have to adopt a more proactive and targeted AI role that focuses on earlier awareness of potential risks. It’s about building models that can recognize patterns across disparate digital channels—identifying that one specific product complaint hidden among thousands of generic comments. By using AI to flag these high-impact signals at speed and scale, we allow our safety experts to focus their energy on investigation rather than data entry. This shift doesn’t just improve efficiency; it fundamentally changes the speed at which we can identify a potential threat to patient safety, making the entire pharmacovigilance lifecycle more responsive and less reactive.
What is your forecast for AI governance in pharmacovigilance?
I believe that over the next few years, governance will evolve from a set of aspirational principles into the absolute table-stakes for survival in the pharmaceutical industry. Organizations that continue to postpone the modernization of their governance models will find themselves facing a “compliance debt” that will be incredibly costly and urgent to remediate when regulators inevitably increase their scrutiny. We will see a shift where transparency, explainability, and demonstrable control become the primary metrics by which a company’s safety department is judged, rather than just the speed of their reporting. Those leaders who act decisively now to establish strong guardrails will not only reduce their regulatory vulnerability but will also gain a significant competitive advantage by being able to scale their operations safely. Ultimately, the goal is to reach a state where regulators have such high confidence in an organization’s AI governance that the technology itself becomes a transparent, trusted component of the global effort to protect patients.
